- Home
- EU vs AKBA Comparison
EU vs AKBA Comparison
Compare EU & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EU | AKBA |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.7M | 375.0M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EU | AKBA |
|---|---|---|
| Price | $1.99 | $1.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $4.00 | ★ $5.25 |
| AVG Volume (30 Days) | 2.2M | ★ 2.2M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.76 | ★ 93.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,155,000.00 | N/A |
| Revenue This Year | $212.11 | N/A |
| Revenue Next Year | $29.88 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.50 | $1.14 |
| 52 Week High | $4.19 | $4.08 |
Technical Indicators
Market Signals| Indicator | EU | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 52.14 |
| Support Level | $1.71 | $1.16 |
| Resistance Level | $2.17 | $1.56 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 58.51 | 45.76 |
Price Performance
Historical ComparisonAbout EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.